On September 19, 2020 Interius Biotherapeutics seeks to eliminate the ex vivo manufacturing step required for many cell and gene therapies through direct viral delivery of genes to immune and blood cells inside patients themselves (Press release, Interius BioTherapeutics, SEP 19, 2020, View Source [SID1234625654]). Potential applications include treatments for a variety of blood disorders, as well as the delivery of chimeric antigen receptors to cytotoxic T-cells to attack various forms of cancer or into regulatory T-cells to address certain types of autoimmune disease. If successful, this new platform technology and approach may lead to significantly more affordable and more accessible cell and gene therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interius was spun-out of Penn by Saar Gill, M.D., Ph.D., Scientific co-director, Transplant & Cell Therapy program at The University of Pennsylvania, and a prominent inventor in the CAR-T field and Bruce Peacock, an experienced biotechnology executive and successful entrepreneur.